Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.
-
Latest News
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 -
Latest News
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 -
Latest News
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025
-
Latest News Neurizon announces the appointment of chief financial officer April 22, 2025
-
Latest News Mesoblast says Ryoncil payer coverage extended to over 100 million Americans April 22, 2025Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.
-
Latest News UQ tests vaccine response in CEPI-backed 150-day ‘moonshot’ challenge April 17, 2025Researchers at the University of Queensland are attempting to create a vaccine in just 150 days to demonstrate their ability to respond to a pandemic as part of a program backed by the Coalition for Epidemic Preparedness Innovations.
-
Latest News Prescient's PTX-100 receives US FDA Fast Track Designation April 17, 2025Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma.
-
Latest News Cartherics announces board changes, including a new chair April 17, 2025Cell therapy company Cartherics has announced the appointment of Professor Bryan Williams as its new board chair and Laurence Nore as a non-executive director.
-
Latest News Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate April 17, 2025Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.
-
Latest News Imricor secures European approval for its Advantage-MR April 17, 2025The company said it plans the commercial launch of the Vision-MR Ablation Catheter and the new AdvantageMR system in June across new and existing sites in Europe.
-
Latest News Botanix secures commitments for $40 million to accelerate Sofdra rollout April 15, 2025Botanix Pharmaceuticals (ASX:BOT) has received commitments from a significant number of new leading Australian and international institutional investors, alongside key existing institutional and sophisticated investors, to raise $40 million.
-
Latest News Neuren confirms primary endpoints for Phase 3 Trial of NNZ-2591 in PMS April 15, 2025Neuren Pharmaceuticals (ASX:NEU) has announced that the primary endpoints for its planned single Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome have been confirmed at a Type C Meeting with the US FDA.
-
Latest News Carina Biotech completes $5 million capital raise April 15, 2025Cell therapy immuno-oncology company Carina Biotech has reported a successful $5 million capital raise from existing and new shareholders.
-
Latest News Argent BioPharma and AusCann enter heads of agreement for cannabinoid drug development April 15, 2025Argent BioPharma (ASX:RGT) and AusCann have signed a strategic heads-of-agreement to advance cannabinoid-based pharmaceutical development.
-
Latest News Noxopharm announces SOF-SKN successfully passes final pre-trial study April 15, 2025Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.
-
Latest News Opthea updates investors, confirming significant staff reduction April 10, 2025Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.
-
Latest News WEHI says study puts first long COVID treatment on horizon April 10, 2025Researchers at the Walter and Eliza Hall Institute of Medical Research have shown that a new drug compound can prevent long COVID symptoms in mice.
-
Latest News Recce announces placement and entitlement offer to support late-stage trial April 10, 2025Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.
-
Latest News Prescient Therapeutics announces the appointment of new non-executive director April 10, 2025Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.
-
Latest News Osteopore secures European approval for custom orthopaedic and cranial implants April 10, 2025Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe.
New Stories
-
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Latest News -
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 - - Latest News -
Neurizon announces the appointment of chief financial officer
April 22, 2025 - - Latest News -
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025 - - Latest News -
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 - - Latest News -
Imricor secures European approval for its Advantage-MR
April 17, 2025 - - Latest News -
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 17, 2025 - - Latest News